☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Hepatocellular Carcinoma
Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma
March 4, 2021
Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study as 1L Therapy for Advanced HCC
September 28, 2020
Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Car...
August 19, 2020
Medivir's MIV-818 Receives EC's Orphan Medicinal Product Designation to Treat Hepatocellular Carcinoma
July 3, 2020
Roche's Tecentriq + Avastin Receives the US FDA's Approval for Unresectable or Metastatic Hepatocellular Carcinoma
June 2, 2020
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive the US FDA's Approval for Patients with Hepatocellular Carcinoma Prior Treat...
March 11, 2020
Load more...
Back to Home